Drug Sponsors

BioAlliance Pharma, Topotarget to merge

Wednesday, April 16, 2014 01:18 PM

BioAlliance Pharma, an innovative company specialized in developing drugs within orphan oncology diseases, and Topotarget, a Scandinavian-based biopharmaceutical company, intend to merge to create an orphan oncology company with highly complementary pipelines of late-stage products addressing significant unmet medical needs.

More... »

WIRB Copernicus Group

Scripps Research Institute launches drug discovery initiative Scripps Advance

Monday, April 14, 2014 03:02 PM

The Scripps Research Institute (TSRI) has announced the formation of Scripps Advance, a new drug discovery initiative to translate early-stage biomedical research projects, both internal and external to TSRI, into clinical development candidates. Scripps Advance's first collaborator in this new endeavor is the Johnson & Johnson Innovation Center in California.

More... »

CRF Health eCOA webinar series

NeoStem to acquire California Stem Cell

Monday, April 14, 2014 03:01 PM

NeoStem, a provider of emerging cellular therapy, has entered into a definitive agreement to acquire California Stem Cell (CSC), an Irvine, Calif.-based stem cell biotechnology company. NeoStem plans to initiate a pivotal phase III trial of Melapuldencel-T, an autologous melanoma initiating (stem) cell immune-based therapy intended to eliminate the tumor cells capable of causing disease recurrence.

More... »

PHARMAC promotes competition to improving patient access to high-cost medicines

Thursday, April 10, 2014 01:55 PM

PHARMAC has announced its intention to test out a contestable fund for high-cost medicines for rare disorders, which could be seeking proposals from pharmaceutical companies by the end of 2014. Promoting competition among suppliers could be the key to improving patients’ access to high-cost medicines for rare disorders, said chief executive Steffan Crausaz. The fund is a response to concerns about access to these medicines that PHARMAC has been hearing from patients through forums and consultations in recent months.

More... »

Roche acquires IQuum to strengthen offerings in molecular diagnostics

Wednesday, April 9, 2014 12:40 PM

Roche has acquired IQuum, a privately held company focused on developing point-of-care offerings for the molecular diagnostics market. Roche will pay IQuum shareholders $275 million upfront and up to $175 million in contingent product-related milestones.

More... »

TetraLogic to acquire Shape Pharmaceuticals

Wednesday, April 9, 2014 12:25 PM

TetraLogic Pharmaceuticals, a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases, will acquire Shape Pharmaceuticals, a privately held biotechnology company developing suberohydroxamic acid phenyl ester (SHAPE), a novel, tissue-targeted HDAC inhibitor in a topical gel formulation to treat stage IA-IIA Cutaneous T-Cell Lymphoma (CTCL), adding a second clinical-stage oncology compound to the TetraLogic portfolio.

More... »

Mallinckrodt acquires Questcor for $5.6 billion

Monday, April 7, 2014 01:17 PM

By Ronald Rosenberg
CenterWatch Staff Writer

Fulfilling a strategy to substantially invest in the specialty pharmaceutical business, Mallinckrodt announced this morning it has entered into a definitive merger agreement with Questcor Pharmaceuticals, a high-growth biopharmaceutical company, in a transaction valued at about $5.6 billion.

More... »

Sun Pharma to acquire Ranbaxy for $4 billion

Monday, April 7, 2014 12:31 PM

India-based Sun Pharma, an international, integrated, specialty pharmaceutical company, will acquire Ranbaxy Laboratories, an integrated, research-based, international pharmaceutical company, in an all-stock transaction.

More... »

Actavis launches Asia Pacific regional headquarters in Singapore

Friday, April 4, 2014 12:01 PM

Actavis, a global specialty pharmaceutical company, has opened its new regional office in Singapore, which will serve as the headquarters for the company's Asia Pacific and Africa (APACA) region.

More... »

Baxter to acquire Chatham Therapeutics

Thursday, April 3, 2014 11:08 AM

Baxter International, a global, diversified healthcare company, has agreed to acquire all of Chatham Therapeutics’ outstanding membership interests. Chatham is a privately held clinical development-stage biotechnology company. As a result, Baxter will acquire Chatham’s developmental gene therapy programs directed toward the development and commercialization of treatments for hemophilia.

More... »

Subscribe to The CenterWatch Monthly
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 28

WCG acquires Alliance Biosciences to expand its biosafety oversight capabilities, ensure compliance

Facilitated review meetings for protocol design catching on, decreasing amendments, complexity

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs